A new Trinity study highlights that fitness may be a more important clinical endpoint for improvement in patients with fatty liver disease during exercise trials, rather than weight loss. The findings have been published in the medical journal Alimentary Pharmacology and Therapeutics.
Metabolic associated fatty liver disease (MAFLD) is a condition characterised by a build-up of fat in the liver. The liver is central to a suite of vital processes in the body including digestion, blood clotting and energy production.
If left untreated MAFLD can lead to serious complications such as liver fibrosis (scarring), cirrhosis, liver failure and liver cancer, as well as cardiovascular and metabolic issues. Risk factors for developing MAFLD include type 2 diabetes and obesity. The global estimated prevalence of MAFLD is 25%, making it the leading cause of chronic liver disease worldwide, and is quickly becoming the leading cause of cirrhosis and liver cancer in liver transplant candidates in the western world.
This new study highlights that increased fitness, the result of aerobic exercise participation, may be a more important clinical endpoint for improvement in MAFLD patients during exercise trials, rather than weight loss.
Release date: 28 July 2020
Source: Trinity College Dublin